Viewing nowCombinationHanubiem Tablets 50/850 mg
Sitagliptin Phosphate 62.04mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Samjin Pharmaceutical Co., Ltd.

MFDS item code 201503216 · Approved 2015.05.27 · Insurance code 647805520
Improvement of glycemic control in patients with type 2 diabetes mellitus
This medication is used to assist in blood sugar control for patients with type 2 diabetes. Sitagliptin and metformin work together to effectively lower blood sugar when combined with dietary and exercise therapies. With consistent use, patients can manage their blood sugar levels stably and contribute to the prevention of complications. Therefore, this medication is used to improve blood sugar control in type 2 diabetes.
For antidiabetic therapy, determine the dose of this medicine based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of the individual components: sitagliptin 100 mg and metformin 2000 mg. This medicine is generally taken twice daily with meals. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. The initial dose of this medicine should be based on the patient's current treatment regimen. 1. Patients not currently receiving metformin: For patients with no previous history of antidiabetic drug treatment who do not achieve adequate glycemic control with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the initial dose is 1 tablet of this medicine 50/500 mg twice daily. The dose may be increased to 1 tablet of this medicine 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine (see Precautions for Use, 2. Patients in whom administration is contraindicated). 2. Patients receiving metformin: - For patients who do not achieve adequate glycemic control with metformin monotherapy, the recommended initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg) plus the patient's current metformin dose. - Patients switching to this medicine from combination therapy with sitagliptin and metformin may start with their current doses of sitagliptin and metformin. 3. Patients who do not achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg). The initial dose of metformin should take into account the patient's blood glucose level and current dose. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. When coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for Use, 5. General Precautions). No studies have evaluated the safety and efficacy of switching patients previously treated with another oral blood glucose-lowering agent to this medicine. Any change in treatment for type 2 diabetes may alter blood glucose control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate [eGFR] ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dosage adjustment. Because the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be carefully monitored every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Patients in whom administration is contraindicated).
This medication contains sitagliptin and metformin and is used for diabetes treatment. Firstly, there is a possibility of hypersensitivity reactions when taking this medication, so if symptoms such as skin rash, hives, or difficulty breathing occur, immediately discontinue use and consult a doctor. Additionally, there is a risk of developing acute pancreatitis, which is a severe inflammation of the pancreas. If abdominal pain, vomiting, or severe abdominal discomfort occurs after taking this medication, it is necessary to go to the hospital immediately. Due to the metformin component, a rare but potentially life-threatening metabolic disorder called lactic acidosis may occur, so if symptoms such as muscle pain, weakness, difficulty breathing, or abdominal pain appear, discontinue use immediately and inform healthcare professionals. Patients with severely impaired kidney function, severe infections, dehydration, acute myocardial infarction, or heart failure should not take this medication and should discontinue it before and after examinations using radiographic contrast agents. Women who are pregnant or may become pregnant, as well as nursing mothers, should not take this medication. Irregular eating habits, excessive exercise, or concurrent use with other medications may increase the risk of hypoglycemia, so caution is required. During treatment, regular kidney function and blood tests are necessary, and checking vitamin B12 levels is advisable. This medication may cause hypoglycemia, so if symptoms such as dizziness, cold sweats, or tremors occur, sugar should be consumed immediately. It is recommended to discontinue taking this medication for a certain period before and after surgery, and to confirm normal kidney function before resuming. Moreover, excessive alcohol consumption should be avoided during treatment, as alcohol may increase the risk of lactic acidosis. Occasionally, severe joint pain or skin disorders may occur during treatment; if any abnormal symptoms arise, consult a physician. Finally, the safety and efficacy of this medication have not been established for use in children, so it is advised that individuals under 18 years of age do not take this medication.
Not everyone experiences these, and they can vary from person to person.
Store this medication in a tightly closed container to prevent air or moisture from entering. It is recommended to keep the storage temperature between 1 and 30 degrees Celsius at room temperature. This will help maintain the effectiveness of the medication for a longer period.
Pink oval film-coated tablets
30 tablets/box [10 tablets/PTPX3]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationSitagliptin Phosphate 62.04mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Samjin Pharmaceutical Co., Ltd.
CombinationSitagliptin Phosphate Hydrate 64.25mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Jongkun Dang Co., Ltd.
CombinationSitagliptin Phosphate Hydrate 64.25mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Jongkundang Co., Ltd.
CombinationSitagliptin Phosphate Hydrate 64.25mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Jongkundang Co., Ltd.
CombinationMetformin Hydrochloride 500mg · Sitagliptin Phosphate Hydrate 64.25mg
Tablet · Prescription medication · Combination
Jong Kun Dang Co., Ltd.
CombinationMetformin Hydrochloride 1000mg · Sitagliptin Phosphate Hydrate 64.25mg
Tablet · Prescription medication · Combination
JongKeunDang Co., Ltd.
CombinationMetformin Hydrochloride 1000mg · Sitagliptin Phosphate Hydrate 128.5mg
Tablet · Prescription medication · Combination
Jongkundang Co., Ltd.
Sitagliptin Phosphate 62.04mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Yuyu Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.